Merck & Co Inc - Company Profile
Powered by 
All the sales intelligence you need on Merck & Co Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Merck & Co Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Merck & Co Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
View moreMerck & Co Inc (Merck) is a biopharmaceutical company that discovers, develops, manufactures, and markets medicines, vaccines, biologic therapies, and animal health products. The company offers prescription medicines under the therapy areas of oncology, vaccines, infectious diseases, cardio-metabolic disorders, immunology, neuroscience, and ophthalmology. It also offers a wide range of veterinary pharmaceuticals; vaccines; health management solutions and services; and identification, traceability, and monitoring products. Merck’s products are provided to drug wholesalers, retailers, hospitals, government agencies, health maintenance organizations, pharmacy benefit managers, other institutions, veterinarians, distributors, animal producers, farmers, and pet owners. It operates manufacturing facilities in North America, South America, Western Europe, Africa, and Asia. Merck is headquartered in Rahway, New Jersey, the US.
Headquarters
United States of America
Address
126 East Lincoln Avenue, P.O. Box 2000, Rahway, New Jersey, 07065
Website
www.merck.com
Telephone
1 908 7404000
No of Employees
75,000
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
MRK (NYSE)
Revenue (2024)
$65.0B
1.3%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
6.6%
(2024 vs 2023)
Market Cap*
$320.0B
Net Profit Margin (2024)
XYZ
5.3%
(2024 vs 2023)
* As of and is in US$
Merck & Co Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Vaccine: | Zetia |
| Influenza Virus Vaccine | Vytorin |
| BCG Vaccine | Integrilin |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In June, the company received approval from the U.S. Food and Drug Administration for CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) to include children and adolescents who have completed a primary pediatric pneumococcal vaccination series. |
| 2026 | Contracts/Agreements | In June, the company entered into an agreement with the ADAP Crisis Task Force to help state AIDS Drug Assistance Programs provide access to its new once-daily HIV treatment IDVYNSO (doravirine/islatravir). |
| 2026 | Acquisitions/Mergers/Takeovers | In May, the company acquired Terns Pharmaceuticals, Inc. for US$6.7 billion. |
Competitor Comparison
| Key Parameters | Merck & Co Inc | Roche Holding AG | Eli Lilly and Co | Pfizer Inc | AbbVie Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | United States of America | United States of America | United States of America |
| City | Rahway | Basel | Indianapolis | New York City | North Chicago |
| State/Province | New Jersey | Basel-Stadt | Indiana | New York | Illinois |
| No. of Employees | 75,000 | 112,774 | 50,605 | 75,000 | 57,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Robert M. Davis | Chief Executive Officer; President; Chairman | Executive Board | 2022 | 59 |
| Caroline Litchfield | Chief Financial Officer; Executive Vice President | Senior Management | 2021 | 57 |
| David M. Williams | Executive Vice President; Chief Information and Digital Officer | Senior Management | 2020 | 57 |
| Betty D. Larson | Executive Vice President; Chief Human Resources Officer | Senior Management | 2024 | 50 |
| Jennifer Zachary | General Counsel; Executive Vice President | Senior Management | 2020 | 48 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer